Loading clinical trials...
Loading clinical trials...
Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, A Single-Arm, Phase II Study (ALPHA Study)
Conditions
Interventions
Afatinib Oral Tablet
Pembrolizumab Injection
Locations
1
Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Start Date
January 24, 2019
Primary Completion Date
April 14, 2022
Completion Date
April 14, 2022
Last Updated
April 21, 2022
NCT06998069
NCT06912087
NCT06303180
NCT05418842
NCT03914378
NCT06003231
Lead Sponsor
National Taiwan University Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions